Israel-based AI-powered drug simulation company QuantHealth has upgraded its platform with its new product Katina, intending to simulate clinical trials on a large scale to streamline and improve the efficiency of drug development.
Katina simulates hundreds of thousands of potential trial protocol combinations using AI to guide researchers through the selection of patient groups, treatment parameters, and different endpoints. Its features include a Monte Carlo workflow for high-volume protocol generation and a built-in scoring system for trial simulation, providing insights to help researchers make decisions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.